M&As this week: Genesis Biotechnology Group, Betta Pharmaceuticals

2nd March 2017 (Last Updated March 2nd, 2017 18:30)

Genesis Biotechnology Group has completed the acquisition of PharmOptima, which will enable the former to provide its customers a single point-of-contact for the development and co-ordination of their unique pre-clinical drug development programme.

Genesis Biotechnology Group has completed the acquisition of PharmOptima, which will enable the former to provide its customers a single point-of-contact for the development and co-ordination of their unique pre-clinical drug development programme.

"Betta Pharmaceuticals has announced its intention to acquire 77.4% stake in AnewPharma."

The acquirer company is a US-based biotechnology firm, whereas the target company is a contract research organisation also based in the US.

Betta Pharmaceuticals has announced its intention to acquire 77.4% stake in AnewPharma.

Both companies involved in the transaction are pharmaceutical organisations based in China.

The purchase consideration for the acquisition is expected to be ¥371.6m ($54.08m).